Checkpoint blockade, such as PD-1/PD-L1 blockade, is a pillar of cancer immunotherapy for several tumor types, including melanoma, and lung, renal, and bladder cancers; however, the efficacy in patients with PDAC remains poor38. Here, CD274 is linked to neoplasm.